BRCA2‐Related Hereditary Cancer Syndrome‐Associated Small Bowel Adenocarcinoma With Multiple BRCA2 Mutations: A Case Report and Review of the Literature

ABSTRACT Background Small bowel adenocarcinomas (SBAs) are rare and aggressive cancers. About one‐fifth of SBA patients have predisposing conditions; among them, there are also genetic tumor syndromes, including Lynch syndrome, familial adenomatous polyposis, and Peutz‐Jeghers syndrome. Although BRC...

Full description

Saved in:
Bibliographic Details
Published inCancer reports Vol. 8; no. 4; pp. e70200 - n/a
Main Authors Antoci, Francesca, Colella, Tommaso, Biletta, Elena, Travaglino, Erica, De Lisi, Giuseppe, Quaquarini, Erica, Arpa, Giovanni, Pisacane, Alberto Maria, Paris, Myriam Katja, Corallo, Salvatore, Di Sabatino, Antonio, Leone, Francesco, Vanoli, Alessandro
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.04.2025
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text
ISSN2573-8348
2573-8348
DOI10.1002/cnr2.70200

Cover

More Information
Summary:ABSTRACT Background Small bowel adenocarcinomas (SBAs) are rare and aggressive cancers. About one‐fifth of SBA patients have predisposing conditions; among them, there are also genetic tumor syndromes, including Lynch syndrome, familial adenomatous polyposis, and Peutz‐Jeghers syndrome. Although BRCA2 mutations, both somatic and germline, have been recently described in SBAs, direct evidence of BRCA2 inactivation in SBA tumor tissue of patients with BRCA2‐related hereditary cancer syndrome is still very limited. Case Presentation Herein, we described a case of a 51‐year‐old woman with a history of breast cancer who developed an adenocarcinoma of the duodeno‐jejunal flexure causing persistent vomiting. After clinical staging, the patient underwent surgical resection, and histologic examination of the specimen confirmed a poorly differentiated adenocarcinoma infiltrating the visceral peritoneum and showing lymph node metastases (stage III, pT4N1). Two years later, the SBA relapsed, and next generation sequencing was performed in matched tumor and normal tissues. In addition to KRAS and TP53 mutations in the tumor, both somatic and germline BRCA2 mutations were identified, indicating biallelic BRCA2 alterations. Conclusion BRCA2‐associated hereditary tumor syndrome could have an etio‐pathogenetic role in SBA development; thus, we suggest that this syndrome should be considered in patients with an SBA diagnosis below the age of 50 years, especially when a personal or family history of breast cancer is present.
Bibliography:The authors received no specific funding for this work.
Funding
Francesca Antoci and Tommaso Colella are co‐first authors.
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
ObjectType-Article-1
ObjectType-Review-5
content type line 23
ObjectType-Case Study-4
ObjectType-Feature-2
ObjectType-Report-3
Funding: The authors received no specific funding for this work.
ISSN:2573-8348
2573-8348
DOI:10.1002/cnr2.70200